Zentalis Pharmaceuticals
@zentalis.com
Zentalis Pharmaceuticals is a clinical-stage company advancing azenosertib, a first-in-class WEE1 inhibitor, for ovarian cancer and other tumor types.
Zentalis Pharmaceuticals's Company Logos
Zentalis Pharmaceuticals's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FF4122
Red Orange
255, 65, 34
8, 100, 57
0, 75, 87, 0
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#330968
Windsor
51, 9, 104
267, 84, 22
51, 91, 0, 59
About Zentalis Pharmaceuticals
Zentalis is an innovative oncology company that is dedicated to developing transformative treatments for cancer. With a patient-centric approach and cutting-edge research, Zentalis aims to make a profound impact in the field of oncology. Their pipeline includes a range of small molecule therapeutics that have differentiated product profiles.
These potential best-in-class candidates include azenosertib, which is a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. Zentalis utilizes their Integrated Discovery Engine to efficiently identify and develop these novel oncology therapies. The company is committed to bettering the lives of patients impacted by cancer and invites motivated individuals to join their vibrant team and contribute to this important mission
Related Brands
Tags
WEE1 kinase inhibition
Oral oncology therapeutics
Biomarker-driven cancer treatment
Clinical-stage drug development
Ovarian cancer
